Form 4: Relay Therapeutics Director Receives Stock Option Grant

Director Lonnel Coats was granted 32,947 stock options in Relay Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Lonnel Coats received a grant of 32,947 stock options on June 9, 2026.
• The options have an exercise price of $14.09 per share.
• The options vest in full on the earlier of the first anniversary of the grant date or the date of the next annual stockholders meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $14.09 exercise price.

Future Outlook

The options vest in full by June 2027 or the next annual meeting, whichever comes first, aligning the director's tenure with upcoming corporate milestones.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain experienced leadership for clinical-stage companies.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard corporate governance practices for mid-cap biotechnology firms.
• The use of time-based vesting is a common industry benchmark for director compensation.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of June 9, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Relay Therapeutics, RLAY, Form 4, Insider Trading, Stock Options, Director Compensation